Crescent Biopharma, Inc.
NASDAQ:CBIOBiotechnology
-$0.49 today
- Market cap
- $482.30M
- Beta
- 1.15
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$5.33
Volume 0.33M
Average 0.28M
CBIO Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Crescent Biopharma, Inc.NASDAQ: CBIO
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow grows, but more slowly than its trailing trend
Q1 FY2026 financing cash flow of $6.95M (cash outflow) rose 367.4% year over year, behind the +699.2% change in trailing-twelve-month financing cash flow. Over 3 fiscal years it compounded at +326.7% a year.
Context
- Financing cash flow amounted to 2978.5% of revenue in FY2025.
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +367.4% toward the trailing-twelve-month pace of +699.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 322.98M USD
- Year-over-year change
- +5983301.3%
- 4-year CAGR
- +134.3%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 322.98M | +5983301.3% |
| FY2024 | 2024-12-31 | 5.4K | -100.0% |
| FY2023 | 2023-12-31 | 28.82M | +593.3% |
| FY2022 | 2022-12-31 | 4.16M | -61.2% |
| FY2021 | 2021-12-31 | 10.72M | — |
Financing Cash Flow vs competitors
How CBIO compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +699.2% is the 6th highest of 8, against a peer median of +5357.5%.
- Financing cash flow amounts to 2659.6% of revenue for CBIO, versus a peer median of 217.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $444.83M USD | +5357.5% | — | 167.2% | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥433.38M CNY | — | +10.9% | — |
| LTM Mar 2026 | $344.93M USD | +4594.2% | +454.4% | 970.5% | |
| LTM Sep 2026 | $327.45M USD | +22878.8% | -16.3% | 292364.3% | |
| LTM Mar 2026 | $316.04M USD | +699.2% | +326.7% | 2659.6% | |
| LTM Jun 2026 | $313M USD | +30.4% | +145.5% | 267.5% | |
| LTM Mar 2026 | $133.79M USD | +14802.1% | +19.6% | — | |
| LTM Mar 2026 | $69.59M USD | +16083.5% | +247.3% | 44.3% | |
| LTM Dec 2025 | $0 USD | — | +210.9% | 0.0% | |
| LTM Mar 2026 | $0 USD | -100.0% | -46.9% | — | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding CBIO) | — | +5357.5% | +82.5% | 217.4% | |
Competitors are the stored peer set for CBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (63.43M) | (46.69M) | (36.9M) | (37.88M) | (149.94M) |
| Depreciation & Amortization | 264.6K | 207.15K | 153.3K | 35.17K | 84K |
| Deferred Income Tax | 2.17K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.09M | 3.86M | 3.56M | 4.77M | 13.3M |
| Change in Working Capital | (1.17M) | (4.66M) | (2.56M) | 1.16M | (13.37M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | (18M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 17.68K | (1.14M) | (102.08K) | (538.81K) | 2.08M |
| Other Working Capital | (1.18M) | (3.52M) | (2.46M) | 1.7M | 2.55M |
| Other Non-Cash Items | 749.04K | 828.51K | 864.87K | 814.48K | 78.4M |
| Operating Cash Flow | (57.49M) | (46.46M) | (34.88M) | (31.1M) | (71.53M) |
| Capital Expenditures | (14.94K) | (84.19K) | (21.39K) | (9.97K) | (919K) |
| Acquisitions (Net) | 0 | 0 | 0 | 30K | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | (72M) |
| Investing Cash Flow | (14.94K) | (84.19K) | (21.39K) | 20.03K | (72.92M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 10.7M | 4.16M | 28.71M | 5.4K | 5K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (177K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 25.03K | 0 | 116.5K | 0 | 323.16M |
| Financing Cash Flow | 10.72M | 4.16M | 28.82M | 5.4K | 322.98M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (46.78M) | (42.38M) | (6.08M) | (31.07M) | 178.53M |
| Free Cash Flow | (57.5M) | (46.54M) | (34.9M) | (31.11M) | (72.45M) |
Crescent Biopharma, Inc.
NASDAQ:CBIO
Intrinsic Alpha fair value
Locked
Current Price
$12.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.